(NasdaqGM:IXHL), Demonstrated bioavailability of IHL-42X, Incannex's proprietary combination formulation, confirming delivery of both dronabinol and acetazolamide Achieved similar PK and equivalent total drug exposure levels of IHL-42X and the reference listed drugs (RLD) for dronabinol and acetazolamide, building a scientific bridge to established safety and toxicology data with the potential to support a future FDA […]

(NASDAQ:RCAT), SAN JUAN, Puerto Rico, Jan. 23, 2025 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced it has secured new orders for its Edge 130 drone from the Army National Guard and

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company's proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential FREMONT, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — Attovia

(NASDAQ:IFRX), JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. About InflaRx InflaRx (Nasdaq: IFRX) is

(NASDAQ:SYBT), LOUISVILLE, Ky., Jan. 23, 2025 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO, and T. Clay

NEW YORK, NY / ACCESSWIRE / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) concerning possible violations of federal securities laws. On January 2, 2025, Neumora announced its experimental depression treatment failed in the first of three studies planned by

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible violations of federal securities laws. On December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial,

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Signet Jewelers Limited ("Signet") (NYSE:SIG) concerning possible violations of federal securities laws. On January 14, 2025, Signet issued a press release announcing the company’s holiday sales results, comprising the 10-week period ending

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ModivCare Inc. ("ModivCare Inc.") (NASDAQ:MODV) concerning possible violations of federal securities laws. On September 12, 2024, ModivCare filed a press release on a Form 8-K. Therein, the Company announced that it would

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain